Profit-driven

In a recent interview, CEO Vas Narasimhan shared a bullish forecast for Novartis, projecting a consistent annual growth rate of at least 5% through 2028. This outlook aims to assuage fears that often accompany the expiration of patents on the company’s blockbuster drugs, particularly given the industry‘s historical precedent of declining revenues when key patents
0 Comments
OpenAI, the trailblazing artificial intelligence company, is on the verge of securing a massive $6.5 billion funding round that could redefine its corporate structure and operational strategies. According to inside sources, this financing is likely to be issued in the form of convertible notes, a decision that significantly signals the company’s growing need for capital
0 Comments
The recent ruling by U.S. District Judge Zahid Quraishi in Trenton, New Jersey, to uphold the law requiring drug manufacturers like Bristol Myers Squibb and Johnson & Johnson to negotiate prices of their blood clot prevention drugs with the U.S government’s Medicare program has sparked controversy in the pharmaceutical industry. Despite the drug companies’ arguments
0 Comments